GLP+ supplies research-grade Tirzepatide across Indonesia. A dual GLP-1 + GIP receptor agonist, available in 10mg vial or pre-filled injector pen. Nationwide delivery, IDR pricing, WhatsApp ordering.
One lab-verified compound, two formats. All prices in IDR, no hidden fees.
The dual-receptor evolution of Semaglutide, activating both GLP-1 and GIP pathways.
Tirzepatide is a dual-action peptide that activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. By engaging two incretin pathways instead of one, Tirzepatide produces a stronger metabolic response in published research than single-receptor agonists like Semaglutide.
The compound has become one of the most-requested weight management peptides in the global research community, particularly for studies on appetite suppression, body composition, and metabolic markers. Its dual mechanism is the reason researchers often choose Tirzepatide when single-receptor protocols have plateaued.
We supply Tirzepatide in two formats. The 10mg vial is the standard research format, requires reconstitution with bacteriostatic water (which we can include with your order), and offers full dosing flexibility. The 10mg pre-filled pen is the same lab-verified peptide loaded into a click-to-dose injector, ready to use straight from the box. Both are tested independently at 99%+ purity.
GLP+ is operated by Peptide+, Indonesia's most-reviewed peptide source with a 5.0-star Google rating from 60 verified customers at our Canggu flagship. Pricing is in Indonesian Rupiah with no hidden fees. Our WhatsApp team responds within minutes during business hours and dispatches nationwide.
The science, translated for non-researchers.
Tirzepatide is a synthetic peptide that mimics two gut hormones at once: GLP-1 and GIP. The dual mechanism is why its published weight reduction numbers are meaningfully larger than single-receptor Semaglutide. It is the middle of the three GLP weight management compounds we carry, between Semaglutide (single) and Retatrutide (triple).
Same appetite mechanism as Semaglutide: slows stomach emptying, signals fullness to your brain. You feel full sooner and stay full longer.
In practice: smaller portions feel normal, snacking urges fade, less food noise between meals.
Improves insulin response so the sugar and fat from what you eat is handled more efficiently. The added GIP receptor is what differentiates Tirzepatide from Semaglutide.
In practice: less of the energy you eat gets stored as new body fat, better post-meal blood-sugar stability.
By engaging two incretin pathways instead of one, Tirzepatide produces a stronger overall metabolic response. Studies have shown it outperforms Semaglutide head-to-head on both weight and HbA1c.
In practice: researchers often choose Tirzepatide when single-receptor protocols have plateaued or for larger metabolic targets.
Real numbers from peer-reviewed publications.
All claims above are from peer-reviewed publications. Tirzepatide is supplied by GLP+ as a research peptide for in-vitro and laboratory use only. We do not provide medical advice, dosing guidance, or treatment recommendations. For citations and published dosing protocols, see our researcher resources page.
Tirzepatide is a dual-action incretin peptide that activates both the GLP-1 and GIP receptors. The dual mechanism produces a stronger metabolic response in published research than single-receptor agonists like Semaglutide.
Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP). Retatrutide activates three (GLP-1, GIP and Glucagon). Tirzepatide sits in the middle, with stronger metabolic response than Semaglutide and longer research history than Retatrutide.
Our current Bali catalog lists 10mg as the standard size for Tirzepatide in both vial and pen. If you need a different size, message us on WhatsApp and we will check availability.
All GLP peptides ship in temperature-controlled packaging with cold-chain protection. Pens and vials arrive intact and ready to refrigerate. Same-day dispatch for orders placed before 5 PM.
Yes. All Tirzepatide sold by GLP+ is intended for research purposes only. We do not provide medical advice, dosing guidance, or treatment recommendations.
Tirzepatide sits between Semaglutide (single receptor) and Retatrutide (triple receptor).
The original GLP-1 weight management peptide. Longest research history, often used as the baseline before stepping up to dual or triple agonists.
Learn about Semaglutide →The newest weight management peptide, activating three receptors. Available in 5mg, 10mg and 30mg with vials from IDR 1,800,000.
Learn about Retatrutide →Get same-day responses from our team. Vial or pen, your choice.
Message Us on WhatsApp